Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Terminated
Trial end date:
2016-02-19
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long term safety and tolerability of
simtuzumab (GS-6624) in participants with idiopathic pulmonary fibrosis (IPF) who had
previously participated in Gilead clinical trial AB0024-201.